Improved survival and reduced alcohol-associated hepatitis risk with renin-angiotensin-aldosterone system inhibitors in alcohol-associated liver disease.

Q: What does this research mean for the field?

ACEI/ARB use in patients with alcohol-associated liver disease is associated with reduced risks of mortality, cardiovascular events, liver events, alcohol-associated hepatitis, and sepsis. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Pojsakorn Danpanichkul; Yanfang Pang; Donghee Kim; Andrew Ibrahim; Primrose Tothanarungroj; Omar Al Ta'ani; Narathorn Kulthamrongsri; Kwanjit Duangsonk; Robert J Wong; Daniel Q Huang; Karn Wijarnpreecha; Mazen Noureddin; Suthat Liangpunsakul

doi:10.1111/acer.70235

February 1, 2026

Improved survival and reduced alcohol-associated hepatitis risk with renin-angiotensin-aldosterone system inhibitors in alcohol-associated liver disease.

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the impact of RAAS inhibitors on outcomes in patients with alcohol-associated liver disease (ALD).
Analyzed data from a large cohort of patients with ALD.
Evaluated the use of ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB).
Assessed outcomes including mortality, cardiovascular events, liver events, alcohol-associated hepatitis (AH), and sepsis.
ACEI/ARB use is associated with lower mortality rates.
Reduced cardiovascular and liver event risks were found in patients using RAAS inhibitors.
A significant decrease in the occurrence of AH and sepsis was observed.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Cohort analysis shows reduced risks of mortality and liver events with RAAS inhibitors in alcohol-associated liver disease, suggesting a protective effect.

Abstract

In this large real-world cohort, ACEI/ARB use in patients with ALD was associated with reduced risks of mortality, cardiovascular events, liver events, AH, and sepsis, supporting a potential protective role of RAAS inhibition in ALD patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Danpanichkul et al. (2026) studied this question.

synapsesocial.com/papers/69a3d89aec16d51705d2f971 https://doi.org/10.1111/acer.70235

View at Publisher

Ask AI

Bookmark

Share

Improved survival and reduced alcohol-associated hepatitis risk with renin-angiotensin-aldosterone system inhibitors in alcohol-associated liver disease.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Improved survival and reduced alcohol-associated hepatitis risk with renin-angiotensin-aldosterone system inhibitors in alcohol-associated liver disease.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading